Furthermore, we observed a close correlation between Def6 expression levels in osteoclast precursors, serum TNF levels from RA patients and the osteoclastogenic capacity of these precursors, indicating that Def6 inhibits excessive osteoclast formation and bone destruction in RA. The gene discussed is DEF6; the disease is rheumatoid arthritis.